Reduction of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody by Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.

MLA

Komai, Toshihiko, et al. “Reduction of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody by Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.” Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, vol. 27, no. 8S, Dec. 2021, pp. S806–07. EBSCOhost, https://doi.org/10.1097/RHU.0000000000001453.

APA

Komai, T., Harada, H., Takahashi, H., Shoda, H., & Fujio, K. (2021). Reduction of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody by Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis. Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, 27(8S), S806–S807. https://doi.org/10.1097/RHU.0000000000001453

Chicago

Komai, Toshihiko, Hiroaki Harada, Hideyuki Takahashi, Hirofumi Shoda, and Keishi Fujio. 2021. “Reduction of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody by Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.” Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases 27 (8S): S806–7. doi:10.1097/RHU.0000000000001453.